NCT02525237UnknownPhase 2
Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Qingdao Municipal Hospital0 sites30 target enrollmentStarted: August 2015Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Sponsor
- Enrollment
- 30
- Primary Endpoint
- Progression Free Survival
Study Overview
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Apatinib combined with S-1 as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients, aged ≥18 years;
- •Histologically confirmed adenocarcinoma of the stomach with inoperable locally advanced or recurrent and/or metastatic disease;
- •Measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST v1.1);
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3;
- •No previous chemotherapy for advanced/metastatic disease 1) Prior adjuvant/neoadjuvant therapy is allowed if at least 6 months has elapsed between completion of adjuvant/neoadjuvant therapy and enrolment into the study); 2) No previous targeted therapy; 3) For patients who can't tolerate first-line chemotherapy or refuse to accept chemotherapy, if they request to participate in this study, may receive apatinib monotherapy after consultation with the principal investigator in consideration of ethics.
- •Hematological, Biochemical and Organ Functions: HB ≥ 80 g/L, ANC ≥ 1.5×109/L, PLT ≥ 80×109/L, BIL < 1.5×ULN, ALT or AST < 2.5×ULN (or < 5×ULN in patients with liver metastases), Serum Cr ≤ 1×ULN, Cr clearance ≥ 50 mL/min;
- •Life expectancy of more than 3 months;
- •Duration from operation is more than 4 weeks;
- •For women of child-bearing age, the pregnancy test results (serum or urine) within 7 days before enrolment must be negative. They will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men (previous surgical sterilization accepted), will take appropriate methods for contraception during the study until the 8th week post the last administration of study drug.
- •Signed informed consent.
Exclusion Criteria
- •Patients with poor-controlled arterial hypertension (systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease, arrhythmia (including QT interval prolongation, for man > 450 ms, for woman > 470 ms), and cardiac dysfunction greater than Class II;
- •Factors affecting the oral medication, such as inability to swallow, chronic diarrhea and intestinal obstruction;
- •Patients with a clear tendency of gastrointestinal bleeding;
- •Abnormal coagulation function (INR > 1.5×ULN, APTT > 1.5×ULN), with tendency of bleed;
- •Pregnant or lactating women;
- •Other conditions regimented at investigators' discretion.
Arms & Interventions
Apatinib plus S-1
Experimental
Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
Intervention: Apatinib (Drug)
Apatinib plus S-1
Experimental
Apatinib (500 mg qd p.o.) concomitantly with S-1 (40 mg/m2 qd days 1-14 q3w p.o.)
Intervention: S-1 (Drug)
Outcomes
Primary Outcomes
Progression Free Survival
Time Frame: Event driven, an expected average of 8 months
Safety will be assessed by incidence of adverse events
Time Frame: An expected average of 8 months
Secondary Outcomes
- Objective response rate (ORR)(An expected average of 8 months)
- Disease control rate (DCR)(An expected average of 8 months)
- Overall survival (OS)(Event driven, an expected average of 24 months)
- Quality of life (QoL)(An expected average of 24 months)
Investigators
Xiaochun Zhang
Chairman
Qingdao Municipal Hospital
Similar Trials
Unknown
Phase 2
Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic CancerAdvanced Pancreatic CancerNCT03662035Changzhou No.2 People's Hospital30
Unknown
Phase 1
Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric CancerGastric CancerNCT03276156Zhejiang Cancer Hospital12
Completed
Phase 2
An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT03129256Changzhou Cancer Hospital of Soochow University52
Unknown
Phase 2
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal CancerColorectal CancerNCT03397199Henan Cancer Hospital120
Unknown
Phase 1
Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLCNon Small Cell Lung CancerCombination ChemotherapyLung CancerApatinibNCT03201146West China Hospital48